Abstract:Background: Mesenchymal stromal cells (MSCs), commonly sourced from adipose tissue, bone marrow and umbilical cord, have been widely used in many medical conditions due to their therapeutic potential. Yet, the still limited understanding of the underlying mechanisms of action hampers clinical translation. Clinical potency can vary considerably depending on tissue source, donor attributes, but importantly, also culture conditions. Lack of standard procedures hinders inter-study comparability and delays the progression of the field. The aim of this study was A- to assess the impact on MSC characteristics when different laboratories, performed analysis on the same MSC material using harmonised culture conditions and B- to understand source-specific differences. Methods: Three independent institutions performed a head-to-head comparison of human-derived adipose (A-), bone marrow (BM-), and umbilical cord (UC-) MSCs using harmonised culture conditions. In each centre, cells from one specific tissue source were isolated and later distributed across the network to assess their biological properties, including cell expansion, immune phenotype, and tri-lineage differentiation (part A). To assess tissue-specific function, angiogenic and immunomodulatory properties and the in vivo biodistribution were compared in one expert lab (part B). Results: By implementing a harmonised manufacturing workflow, we obtained largely reproducible results across three independent laboratories in part A of our study. Unique growth patterns and differentiation potential were observed for each tissue source, with similar trends observed between centres. Immune phenotyping verified expression of typical MSC surface markers and absence of contaminating surface markers. Depending on the established protocols in the different laboratories, quantitative data varied slightly. Functional experiments in part B concluded that conditioned media from BM-MSCs significantly enhanced tubulogenesis and endothelial migration in vitro. In contrast, immunomodulatory studies reported superior immunosuppressive abilities for A-MSCs. Biodistribution studies in healthy mice showed lung entrapment after administration of all three types of MSCs, with a significantly faster clearance of BM-MSCs. Conclusion: These results show the heterogeneous behaviour and regenerative properties of MSCs as a reflection of intrinsic tissue-origin properties while providing evidence that the use of harmonised culture procedures can reduce but do not eliminate inter-lab and operator differences.

Mesenchymal stromal cells (MSCs): science and f(r)iction

Mesenchymal stem cells biological and biotechnological advances: Implications for clinical applications

Clinical implications of differential functional capacity between tissue-specific human mesenchymal stromal/stem cells

Concise Review: Mesenchymal Stem Cells: From Roots to Boost

Mesenchymal Stem Cells: Molecular Characteristics and Clinical Applications

Mesenchymal stem cells: Cell therapy and regeneration potential

Metabolic Regulation of Mesenchymal Stem Cell in Expansion and Therapeutic Application

MSCs: Biological Characteristics, Clinical Applications and Their Outstanding Concerns

Mesenchymal stem cell perspective: cell biology to clinical progress

Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application

Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach

Controversies regarding transplantation of mesenchymal stem cells

Concise Review: Mesenchymal Stem Cells in Cardiovascular Regeneration: Emerging Research Directions and Clinical Applications

Critical View on Mesenchymal Stromal Cells in Regenerative Medicine

Mesenchymal Stem Cells – Sources and Clinical Applications

Mesenchymal Stem Cell Preparations—Comparing Apples and Oranges

Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine

Inter- and Intra-donor variability in bone marrow-derived mesenchymal stromal cells: implications for clinical applications

Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities

Mesenchymal Stem/Stromal Cells in Liver Fibrosis: Recent Findings, Old/New Caveats and Future Perspectives

Are Mesenchymal Stem Cells Fibroblasts with Benefits?